RecruitingPhase 1NCT07137338

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

Studying Dilated cardiomyopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rocket Pharmaceuticals Inc.
Intervention
RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)(genetic)
Enrollment
8 enrolled
Eligibility
18-65 years · All sexes
Timeline
20262029

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07137338 on ClinicalTrials.gov

Other trials for Dilated cardiomyopathy

Additional recruiting or active studies for the same condition.

See all trials for Dilated cardiomyopathy

← Back to all trials